Literature DB >> 8690756

Analysis of thrombocytopenia due to carboplatin combined with etoposide in elderly patients with lung cancer.

K Shibata1, Y Nakatsumi, K Kasahara, T Bando, M Fujimura, T Matsuda.   

Abstract

Thrombocytopenia induced by carboplatin combined with etoposide for elderly lung cancer patients was analyzed in relation to the predicted thrombocytopenia by the equations advocated by Egorin et al. and Taguchi et al. The thrombocytopenia actually observed was strongly correlated with and significantly more severe than that predicted if carboplatin had been administered as a single agent. The AUC (area under the curve) of carboplatin predicted by Calvert's equation significantly affected the degree of thrombocytopenia. These data suggested that dosing of carboplatin should be determined individually on the basis of renal function, as recommended earlier. The reason for the enhancement of thrombocytopenia is yet to be determined in future trials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690756     DOI: 10.1007/bf01212885

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  27 in total

1.  Needed: clinical trials for older patients.

Authors:  B J Kennedy
Journal:  J Clin Oncol       Date:  1991-05       Impact factor: 44.544

2.  Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group.

Authors:  C B Begg; P P Carbone
Journal:  Cancer       Date:  1983-12-01       Impact factor: 6.860

3.  Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.

Authors:  I E Smith; B D Evans; M E Gore; M D Vincent; L Repetto; J R Yarnold; H T Ford
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

4.  Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy.

Authors:  A Lindemann; F Herrmann; W Oster; G Haffner; W Meyenburg; L M Souza; R Mertelsmann
Journal:  Blood       Date:  1989-12       Impact factor: 22.113

5.  Phase II studies with carboplatin in non-small cell lung cancer.

Authors:  U Gatzemeier; M Heckmayr; R Neuhauss; D Hossfeld; W Achterrath; L Lenaz
Journal:  Semin Oncol       Date:  1990-02       Impact factor: 4.929

Review 6.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

7.  Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions.

Authors:  K H Pflüger; M Hahn; J B Holz; L Schmidt; P Köhl; H W Fritsch; H Jungclas; K Havemann
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on circulating platelets.

Authors:  H J Avenarius; M Freund; J Deinhardt; H Poliwoda
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

Review 9.  Etoposide (VP-16-213).

Authors:  B F Issell; S T Crooke
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

10.  Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer.

Authors:  U Gatzemeier; D K Hossfeld; R Neuhauss; M Reck; W Achterrath; L Lenaz
Journal:  J Clin Oncol       Date:  1992-05       Impact factor: 44.544

View more
  1 in total

Review 1.  Treatment and outcomes for elderly patients with small cell lung cancer.

Authors:  R J Stephens; D H Johnson
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.